Vidarbha News

Aneurysmal Subarachnoid Hemorrhage Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Aneurysmal Subarachnoid Hemorrhage Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

March 27
17:16 2020
Aneurysmal Subarachnoid Hemorrhage Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

Aneurysmal Subarachnoid Hemorrhage (aSAH) – Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight launched a new report on Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Aneurysmal Subarachnoid Hemorrhage (aSAH) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (aSAH) , historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (aSAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the report

1. The estimated incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) to be 6–8 per 100,000 annually.
2. It has been found that majority of the cases are of Grade 1&2, followed by Grade 4&5, and least are contribute by Grade 3.

Key benefits of the report

1. Aneurysmal Subarachnoid Hemorrhage (aSAH) market report covers a descriptive overview and comprehensive insight of the Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology and Aneurysmal Subarachnoid Hemorrhage (aSAH) market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Aneurysmal Subarachnoid Hemorrhage (aSAH) market report provides insights into the current and emerging therapies.
3. Aneurysmal Subarachnoid Hemorrhage (aSAH) market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Aneurysmal Subarachnoid Hemorrhage (aSAH) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Aneurysmal Subarachnoid Hemorrhage (aSAH) market.

 

Request for sample pages : https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-market

 

According to Delveinsight, Aneurysmal Subarachnoid Hemorrhage (aSAH) is more common in females.”

 

Aneurysmal Subarachnoid Hemorrhage (aSAH) is a serious condition that not just affects the brain, but multiple other organ systems as well. Despite a steady reduction of mortality from acute SAH in recent years, from over half to approximately one-third, this entity is still associated with considerable morbidity and mortality.

Aneurysmal subarachnoid hemorrhage (aSAH) is a worldwide health burden with high fatality and permanent disability rates. These aneurysms, located at the branching point of proximal intracranial arteries, are not uncommon and found in about 2% of the adult population (and even more frequently in those with a family history of aSAH or polycystic kidney disease).

Risk factors for aneurysm rupture include hypertension, smoking, heavy alcohol use, and cocaine abuse. Mortality can be as high as 50%, with 10–20% of patients dying within the first 24 h from cardiac arrhythmias or cerebral herniation.

Delayed ischemic neurologic deficit (DIND; also referred to as clinical/symptomatic vasospasm or delayed cerebral ischemia) is a serious and poorly understood complication of aSAH, occurring in 20–40% of patients.

Several grading systems are used to assess the initial clinical and radiologic features of subarachnoid hemorrhage. The two most widely used clinical scales are those of Hunt and Hess and the World Federation of Neurological Surgeons. The latter is currently preferred since it is based on the sum score of the Glasgow Coma Scale (a very reliable method for evaluating the level of consciousness) and the presence of focal neurologic signs.

The incidence of aSAH has been shown to be associated with numerous nonmodifiable (age, gender, ethnicity, family history, aneurysm location, and size) and modifiable (hypertension, body mass index, tobacco, and illicit drug use) risk factors. Although early repair of ruptured aneurysms and aggressive postoperative management has improved the overall outcomes.

The treatment of aneurysmal subarachnoid hemorrhage (aSAH) was subject to fundamental changes in the last two decades. The introduction of endovascular coiling, beside the wellestablished method of neurosurgical clipping, extended the treatment options in aSAH. With the evolution of endovascular procedures, the availability of coiling became more widespread.

The launch of the emerging therapies is expected to significantly impact Aneurysmal Subarachnoid Hemorrhage (aSAH) treatment scenario in the upcoming years:-

Drugs covered:

  1. SFX-01
  2. Clazosentan

And many others

The key players in Aneurysmal Subarachnoid Hemorrhage (aSAH) market are:

  1. Evgen Pharma
  2. Actelion Pharmaceuticals
    And many others

 

Request For Sample Pages: https://www.delveinsight.com/sample-request/aneurysmal-subarachnoid-hemorrhage-sah-market

 

Table of contents

1. Report Introduction

2. Executive Summary of Aneurysmal Subarachnoid Hemorrhage (aSAH)

3. Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Share at a glance

3.1. Seven Major Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in 2017

3.2. Seven Major Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH) in 2030

4. Disease Background and Overview

4.1. Causes

4.2. Signs and symptoms

4.3. Pathophysiology

4.4. Risk Factors

4.5. Diagnosis

5. Epidemiology and Patient Population

5.1. Assumptions and Caveats

5.2. Total Incident Cases of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM (2017–2030)

5.3. Gender-specific Cases of aSAH in the 7MM (2017–2030)

5.4. Grade-specific Cases of aSAH in the 7MM (2017–2030)

5.5. Clinical manifestation associated with aSAH in the 7MM (2017–2030)

5.6. Treatable Cases of aSAH in the 7MM (2017–2030)

6. Country Wise: Epidemiology of Aneurysmal Subarachnoid Hemorrhage (aSAH)

6.1. United States

6.2. EU5

6.2.1. Germany

6.2.2. France

6.2.3. Italy

6.2.4. Spain

6.2.5. United Kingdom

6.3. Japan

6.4. Incident Cases of Aneurysmal Subarachnoid Hemorrhage (aSAH) (2017–2030)

6.5. Gender-specific Cases of aSAH (2017–2030)

6.6. Grade-specific Cases of aSAH (2017–2030)

6.7. Clinical manifestation associated with aSAH (2017–2030)

6.8. Treatable Cases of aSAH (2017–2030)

7. Current Treatment and Medical Practices

7.1. Treatment Algorithm

7.2. Guidelines and Recommendations for Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

7.2.1. United States

7.2.2. Europe

7.2.3. Japan

8. Marketed Drugs

8.1. Nymalize: Arbor Pharmaceuticals

To be continued in the report…

9. Current Unmet Needs of Aneurysmal Subarachnoid Hemorrhage (aSAH)

10. Emerging Therapeutics

10.1. Key Cross Competition

10.2.SFX-01: Evgen

10.3.Clazosentan: Actelion Pharmaceutical

To be continued in the report…

11. Market Size of Aneurysmal Subarachnoid Hemorrhage (aSAH)

11.1. Total 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH) market analysis (2017–2030)

11.2. Total 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH) market analysis by therapies (2017–2030)

12. Region-Wise Market size of Aneurysmal Subarachnoid Hemorrhage (aSAH)

12.1.United States

12.2.EU-5

12.3.Japan

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Reimbursement

17. Appendix

18. Report Methodology

18.1. Sources Used

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

                                          
Related Reports:

Aneurysmal Subarachnoid Hemorrhage (aSAH) – Pipeline Insights, 2020

The Aneurysmal Subarachnoid Hemorrhage (aSAH) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Aneurysmal Subarachnoid Hemorrhage (aSAH) across the complete product development cycle, including all clinical and nonclinical stages.

Aneurysmal Subarachnoid Hemorrhage (aSAH) – Epidemiology Forecast to 2030

The Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology covered in the report provides historical as well as forecasted Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/